Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 5/20 | 0.33 |
| ▸ | TDO2 | P48775 | 5/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23869733 | 0.95 | IDO1 (0.33) | IDO1TDO2SMN1; SMN2POLBTTR | |
| SCHEMBL25890662 | 0.82 | TDO2 (0.38) | IDO1TDO2SMN1; SMN2POLBTTR | |
| SCHEMBL23869696 | 0.78 | MAPT (0.38) | IDO1TDO2SMN1; SMN2MAPTDHODH | |
| SCHEMBL16980287 | 0.77 | CHRM2 (0.34) | IDO1TDO2CES1 | |
| SCHEMBL25890747 | 0.77 | TDO2 (0.38) | IDO1TDO2SMN1; SMN2POLBTTR | |
| SCHEMBL25895952 | 0.75 | TOP2A (0.43) | IDO1TDO2SMN1; SMN2MAPTDHODH | |
| SCHEMBL25162197 | 0.73 | PGR (0.32) | — | |
| SCHEMBL16980276 | 0.72 | SMN1; SMN2 (0.32) | SMN1; SMN2GAAMAPT | |
| SCHEMBL20807653 | 0.72 | TSHR (0.32) | SMN1; SMN2GAA | |
| SCHEMBL25161924 | 0.71 | PGR (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210308207-A1 | COMPOUNDS COMPRISING A LINKER FOR INCREASING TRANSCYCLOOCTENE STABILITY | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-10-07 | — | — | US | disclosed |
| US-20210299286-A1 | TETRAZINES FOR HIGH CLICK CONJUGATION YIELD IN VIVO AND HIGH CLICK RELEASE YIELD | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299286-A1 | TETRAZINES FOR HIGH CLICK CONJUGATION YIELD IN VIVO AND HIGH CLICK RELEASE YIELD | FCER2, SQLE, TTL | IDO1 565/4885TDO2 10/4885SMN1; SMN2 4579/4885 |
| US-20210308207-A1 | COMPOUNDS COMPRISING A LINKER FOR INCREASING TRANSCYCLOOCTENE STABILITY | VIP, PIN1, QPCT | IDO1 1548/4885TDO2 723/4885SMN1; SMN2 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.